The PPARα-FABP1 axis: a new target for NASH therapies?
Authors: Yan T, Luo Y, Yan N et al.
Published in Hepatology 2023
Although it is known that non-alcoholic steatohepatitis (NASH) increases the risk of end-stage liver diseases such as cirrhosis and hepatocellular carcinoma, no pharmacologic therapy has yet been approved to treat it.
Read More